Table I.
Risks of total infections, upper respiratory infections, and nasopharyngitis in hidradenitis suppurativa patients taking adalimumab vs placebo∗
| Trial | Patients, No. |
Total infections, No. (%) |
Upper respiratory tract infections, No. (%) |
Nasopharyngitis, No. (%) |
||||
|---|---|---|---|---|---|---|---|---|
| Adalimumab | Placebo | Adalimumab | Placebo | Adalimumab | Placebo | Adalimumab | Placebo | |
| PIONEER I | 152 | 153 | 40 (26) | 32 (21) | 4 (2.6) | 5 (3.3) | 16 (10.5) | 9 (5.9) |
| PIONEER II | 163 | 163 | 37 (23) | 36 (22) | 9 (5.5) | 8 (4.9) | 10 (6.1) | 9 (5.5) |
| Total | 315 | 316 | 77 (24) | 68 (21.5) | 13 (4.1) | 13 (4.1) | 26 (8.2) | 18 (5.7) |
∗
Data from period 1 of the Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (PIONEER) I and II trials.